|
1
|
Sutherland SM, Kaddourah A, Gillespie SE,
Soranno DE, Woroniecki RP, Basu RK and Zappitelli M; Assessment of
the Worldwide Acute Kidney Injury, Renal Angina and Epidemiology
(AWARE) Investigators: Cumulative application of creatinine and
urine output staging optimizes the kidney disease: Improving global
outcomes definition and identifies increased mortality risk in
hospitalized patients with acute kidney injury. Crit Care Med.
49:1912–1922. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chawla LS, Bellomo R, Bihorac A, Goldstein
SL, Siew ED, Bagshaw SM, Bittleman D, Cruz D, Endre Z, Fitzgerald
RL, et al: Acute kidney disease and renal recovery: Consensus
report of the acute disease quality initiative (ADQI) 16 workgroup.
Nat Rev Nephrol. 13:241–257. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fu Y and Dong Z: Immune response in
COVID-19-associated acute kidney injury and maladaptive kidney
repair. Integr Med Nephrol Androl. 10:e000222023. View Article : Google Scholar
|
|
4
|
Zhu Z, Hu J, Chen Z, Feng J, Yang X, Liang
W and Ding G: Transition of acute kidney injury to chronic kidney
disease: Role of metabolic reprogramming. Metabolism.
131:1551942022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Niculae A, Gherghina ME, Peride I, Tiglis
M, Nechita AM and Checherita IA: Pathway from acute kidney injury
to chronic kidney disease: Molecules involved in renal fibrosis.
Int J Mol Sci. 24:140192023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Neyra JA and Chawla LS: Acute kidney
disease to chronic kidney disease. Crit Care Clin. 37:453–474.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nangaku M, Hirakawa Y, Mimura I, Inagi R
and Tanaka T: Epigenetic changes in the acute kidney
injury-to-chronic kidney disease transition. Nephron. 137:256–259.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Koh ES and Chung S: Recent update on acute
kidney injury-to-chronic kidney disease transition. Yonsei Med J.
65:247–256. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Venkatachalam MA, Weinberg JM, Kriz W and
Bidani AK: Failed tubule recovery, AKI-CKD transition, and kidney
disease progression. J Am Soc Nephrol. 26:1765–1776. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guo R, Duan J, Pan S, Cheng F, Qiao Y,
Feng Q, Liu D and Liu Z: The road from AKI to CKD: Molecular
mechanisms and therapeutic targets of ferroptosis. Cell Death Dis.
14:4262023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
André C, Bodeau S, Kamel S, Bennis Y and
Caillard P: The AKI-to-CKD transition: The role of uremic toxins.
Int J Mol Sci. 24:161522023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Song Z and Gong X: Research progress on
the potential mechanisms of acute kidney injury and chronic kidney
disease induced by proton pump inhibitors. Integr Med Nephrol
Androl. 10:e000272023. View Article : Google Scholar
|
|
13
|
Yu XY, Sun Q, Zhang YM, Zou L and Zhao YY:
TGF-β/Smad signaling pathway in tubulointerstitial fibrosis. Front
Pharmacol. 13:8605882022. View Article : Google Scholar
|
|
14
|
Ma TT and Meng XM: TGF-β/Smad and renal
fibrosis. Adv Exp Med Biol. 1165:347–364. 2019. View Article : Google Scholar
|
|
15
|
Lan HY and Chung ACK: TGF-β/Smad signaling
in kidney disease. Semin Nephrol. 32:236–243. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lan HY: Diverse roles of TGF-β/Smads in
renal fibrosis and inflammation. Int J Biol Sci. 7:1056–1067. 2011.
View Article : Google Scholar :
|
|
17
|
Zou LL, Li JR, Li H, Tan JL, Wang MX, Liu
NN, Gao RM, Yan HY, Wang XK, Dong B, et al: TGF-β isoforms inhibit
hepatitis C virus propagation in transforming growth factor
beta/SMAD protein signalling pathway dependent and independent
manners. J Cell Mol Med. 25:3498–3510. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sultana M, Tayyab M, Sunil, Parveen S,
Hussain M, Saeed S, Riaz Z and Shabbir S: In silico molecular
characterization of TGF-β gene family in Bufo bufo: Genome-wide
analysis. J Biomol Struct Dyn. Feb 12–2024.Epub ahead of print.
View Article : Google Scholar
|
|
19
|
Chen T, Zhu C, Wang X, Pan Y and Huang B:
Asiatic acid encapsulated exosomes of hepatocellular carcinoma
inhibit epithelial-mesenchymal transition through transforming
growth factor beta/smad signaling pathway. J Biomed Nanotechnol.
17:2338–2350. 2021. View Article : Google Scholar
|
|
20
|
Chen Y, Di C, Zhang X, Wang J, Wang F, Yan
JF, Xu C, Zhang J, Zhang Q, Li H, et al: Transforming growth factor
β signaling pathway: A promising therapeutic target for cancer. J
Cell Physiol. 235:1903–1914. 2020. View Article : Google Scholar
|
|
21
|
de Larco JE and Todaro GJ: Growth factors
from murine sarcoma virus-transformed cells. Proc Natl Acad Sci
USA. 75:4001–4005. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang HL, Wang L, Zhao CY and Lan HY: Role
of TGF-beta signaling in beta cell proliferation and function in
diabetes. Biomolecules. 12:3732022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kahata K, Dadras MS and Moustakas A: TGF-β
family signaling in epithelial differentiation and
epithelial-mesenchymal transition. Cold Spring Harb Perspect Biol.
10:a0221942018. View Article : Google Scholar
|
|
24
|
Song J and Shi W: The concomitant
apoptosis and EMT underlie the fundamental functions of TGF-β. Acta
Biochim Biophys Sin (Shanghai). 50:91–97. 2018. View Article : Google Scholar
|
|
25
|
Peng D, Fu M, Wang M, Wei Y and Wei X:
Targeting TGF-β signal transduction for fibrosis and cancer
therapy. Mol Cancer. 21:1042022. View Article : Google Scholar
|
|
26
|
Roberts AB, Anzano MA, Lamb LC, Smith JM
and Sporn MB: New class of transforming growth factors potentiated
by epidermal growth factor: Isolation from non-neoplastic tissues.
Proc Natl Acad Sci USA. 78:5339–5343. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Moses HL, Branum EL, Proper JA and
Robinson RA: Transforming growth factor production by chemically
transformed cells. Cancer Res. 41:2842–2848. 1981.PubMed/NCBI
|
|
28
|
Roberts AB, Anzano MA, Meyers CA, Wideman
J, Blacher R, Pan YC, Stein S, Lehrman SR, Smith JM, Lamb LC, et
al: Purification and properties of a type beta transforming growth
factor from bovine kidney. Biochemistry. 22:5692–5698. 1983.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Derynck R, Jarrett JA, Chen EY, Eaton DH,
Bell JR, Assoian RK, Roberts AB, Sporn MB and Goeddel DV: Human
transforming growth factor-beta complementary DNA sequence and
expression in normal and transformed cells. Nature. 316:701–705.
1985. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cheifetz S, Weatherbee JA, Tsang ML,
Anderson JK, Mole JE, Lucas R and Massagué J: The transforming
growth factor-beta system, a complex pattern of cross-reactive
ligands and receptors. Cell. 48:409–415. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
ten Dijke P, Hansen P, Iwata KK, Pieler C
and Foulkes JG: Identification of another member of the
transforming growth factor type beta gene family. Proc Natl Acad
Sci USA. 85:4715–4719. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Derynck R, Lindquist PB, Lee A, Wen D,
Tamm J, Graycar JL, Rhee L, Mason AJ, Miller DA, Coffey RJ, et al:
A new type of transforming growth factor-beta, TGF-beta 3. EMBO J.
7:3737–3743. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Connor TB Jr, Roberts AB, Sporn MB,
Danielpour D, Dart LL, Michels RG, de Bustros S, Enger C, Kato H,
Lansing M, et al: Correlation of fibrosis and transforming growth
factor-beta type 2 levels in the eye. J Clin Invest. 83:1661–1666.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Border WA, Okuda S, Languino LR, Sporn MB
and Ruoslahti E: Suppression of experimental glomerulonephritis by
antiserum against transforming growth factor beta 1. Nature.
346:371–374. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pierce DF Jr, Gorska AE, Chytil A, Meise
KS, Page DL, Coffey RJ Jr and Moses HL: Mammary tumor suppression
by transforming growth factor beta 1 transgene expression. Proc
Natl Acad Sci USA. 92:4254–4258. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Markowitz S, Wang J, Myeroff L, Parsons R,
Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein
B, et al: Inactivation of the type II TGF-beta receptor in colon
cancer cells with microsatellite instability. Science.
268:1336–1338. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang Y, Feng X, We R and Derynck R:
Receptor-associated Mad homologues synergize as effectors of the
TGF-beta response. Nature. 383:168–172. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Eppert K, Scherer SW, Ozcelik H, Pirone R,
Hoodless P, Kim H, Tsui LC, Bapat B, Gallinger S, Andrulis IL, et
al: MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related
protein that is functionally mutated in colorectal carcinoma. Cell.
86:543–552. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fakhrai H, Mantil JC, Liu L, Nicholson GL,
Murphy-Satter CS, Ruppert J and Shawler DL: Phase I clinical trial
of a TGF-beta antisense-modified tumor cell vaccine in patients
with advanced glioma. Cancer Gene Ther. 13:1052–1060. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Trachtman H, Fervenza FC, Gipson DS,
Heering P, Jayne DR, Peters H, Rota S, Remuzzi G, Rump LC, Sellin
LK, et al: A phase 1, single-dose study of fresolimumab, an
anti-TGF-β antibody, in treatment-resistant primary focal segmental
glomerulosclerosis. Kidney Int. 79:1236–1243. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
King TE Jr, Bradford WZ, Castro-Bernardini
S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM,
Kardatzke D, Lancaster L, et al: A phase 3 trial of pirfenidone in
patients with idiopathic pulmonary fibrosis. N Engl J Med.
370:2083–2092. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Rodon J, Carducci MA, Sepulveda-Sánchez
JM, Azaro A, Calvo E, Seoane J, Braña I, Sicart E, Gueorguieva I,
Cleverly AL, et al: First-in-human dose study of the novel
transforming growth factor-β receptor I kinase inhibitor LY2157299
monohydrate in patients with advanced cancer and glioma. Clin
Cancer Res. 21:553–560. 2015. View Article : Google Scholar
|
|
43
|
Yang S, Yang G, Wang X, Xiang J, Kang L
and Liang Z: SIRT2 alleviated renal fibrosis by deacetylating SMAD2
and SMAD3 in renal tubular epithelial cells. Cell Death Dis.
14:6462023. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Miyazawa K, Itoh Y, Fu H and Miyazono K:
Receptor-activated transcription factors and beyond: Multiple modes
of Smad2/3-dependent transmission of TGF-β signaling. J Biol Chem.
300:1072562024. View Article : Google Scholar
|
|
45
|
Massagué J: TGF-beta signal transduction.
Annu Rev Biochem. 67:753–791. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Itoh S and ten Dijke P: Negative
regulation of TGF-beta receptor/Smad signal transduction. Curr Opin
Cell Biol. 19:176–184. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Moustakas A and Heldin CH: The regulation
of TGFbeta signal transduction. Development. 136:3699–3714. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Meng XM, Nikolic-Paterson DJ and Lan HY:
TGF-β: The master regulator of fibrosis. Nat Rev Nephrol.
12:325–338. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Derynck R and Budi EH: Specificity,
versatility, and control of TGF-β family signaling. Sci Signal.
12:eaav51832019. View Article : Google Scholar
|
|
50
|
Gewin LS: Transforming growth factor-β in
the acute kidney injury to chronic kidney disease transition.
Nephron. 143:154–157. 2019. View Article : Google Scholar
|
|
51
|
Yang Q, Ren GL, Wei B, Jin J, Huang XR,
Shao W, Li J, Meng XM and Lan HY: Conditional knockout of
TGF-βRII/Smad2 signals protects against acute renal injury by
alleviating cell necroptosis, apoptosis and inflammation.
Theranostics. 9:8277–8293. 2019. View Article : Google Scholar :
|
|
52
|
Gewin L: The many talents of transforming
growth factor-β in the kidney. Curr Opin Nephrol Hypertens.
28:203–210. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Hoi S, Tsuchiya H, Itaba N, Suzuki K, Oka
H, Morimoto M, Takata T, Isomoto H and Shiota G: WNT/β-catenin
signal inhibitor IC-2-derived small-molecule compounds suppress
TGF-β1-induced fibrogenic response of renal epithelial cells by
inhibiting SMAD2/3 signalling. Clin Exp Pharmacol Physiol.
47:940–946. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Li J, Zou Y, Kantapan J, Su H, Wang L and
Dechsupa N: TGF-β/Smad signaling in chronic kidney disease:
Exploring post-translational regulatory perspectives (review). Mol
Med Rep. 30:1432024. View Article : Google Scholar
|
|
55
|
Chen DQ, Cao G, Zhao H, Chen L, Yang T,
Wang M, Vaziri ND, Guo Y and Zhao YY: Combined melatonin and
poricoic acid A inhibits renal fibrosis through modulating the
interaction of Smad3 and β-catenin pathway in AKI-to-CKD continuum.
Ther Adv Chronic Dis. 10:20406223198691162019. View Article : Google Scholar
|
|
56
|
Kim IY, Song SH, Seong EY, Lee DW, Bae SS
and Lee SB: Akt1 is involved in renal fibrosis and tubular
apoptosis in a murine model of acute kidney injury-to-chronic
kidney disease transition. Exp Cell Res. 424:1135092023. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Liu W, Li F, Guo D, Du C, Zhao S, Li J,
Yan Z and Hao J: Schisandrin B alleviates renal tubular cell
epithelial-mesenchymal transition and mitochondrial dysfunction by
kielin/chordin-like protein upregulation via Akt pathway
inactivation and adenosine 5′-monophosphate, AMP)-activated protein
kinase pathway activation in diabetic kidney disease. Molecules.
28:78512023. View Article : Google Scholar
|
|
58
|
Kim IY, Park YK, Song SH, Seong EY, Lee
DW, Bae SS and Lee SB: Role of Akt1 in renal fibrosis and tubular
dedifferentiation during the progression of acute kidney injury to
chronic kidney disease. Korean J Intern Med. 36:962–974. 2021.
View Article : Google Scholar :
|
|
59
|
Zhou L, Chen X, Lu M, Wu Q, Yuan Q, Hu C,
Miao J, Zhang Y, Li H, Hou FF, et al: Wnt/β-catenin links oxidative
stress to podocyte injury and proteinuria. Kidney Int. 95:830–845.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Feng Y, Liang Y, Ren J and Dai C:
Canonical Wnt signaling promotes macrophage proliferation during
kidney fibrosis. Kidney Dis (Basel). 4:95–103. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Djudjaj S and Boor P: Cellular and
molecular mechanisms of kidney fibrosis. Mol Aspects Med. 65:16–36.
2019. View Article : Google Scholar
|
|
62
|
Finke M, Kümpers P and Rovas A:
Epidemiology and causes of acute renal failure and transition to
chronic kidney disease. Dtsch Med Wochenschr. 147:227–235. 2022.In
German. PubMed/NCBI
|
|
63
|
Leng X, Li Q, Chen W, Feng H, Li L, Yu L,
Huang P, Ma P and Xie F: C-176 inhibits macrophage polarization
towards M1-subtype and ameliorates LPS induced acute kidney injury.
Eur J Pharmacol. 984:1770282024. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Ibrahim H, Sharawy MH, Hamed MF and
Abu-Elsaad N: Peficitinib halts acute kidney injury via JAK/STAT3
and growth factors immunomodulation. Eur J Pharmacol.
984:1770202024. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Guzzi F, Cirillo L, Roperto RM, Romagnani
P and Lazzeri E: Molecular mechanisms of the acute kidney injury to
chronic kidney disease transition: An updated view. Int J Mol Sci.
20:49412019. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Belavgeni A, Meyer C, Stumpf J, Hugo C and
Linkermann A: Ferroptosis and necroptosis in the kidney. Cell Chem
Biol. 27:448–462. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Luo K: Signaling cross talk between
TGF-β/Smad and other signaling pathways. Cold Spring Harb Perspect
Biol. 9:a0221372017. View Article : Google Scholar
|
|
68
|
Seoane J, Le HV, Shen L, Anderson SA and
Massagué J: Integration of Smad and forkhead pathways in the
control of neuroepithelial and glioblastoma cell proliferation.
Cell. 117:211–223. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Conery AR, Cao Y, Thompson EA, Townsend CM
Jr, Ko TC and Luo K: Akt interacts directly with Smad3 to regulate
the sensitivity to TGF-beta induced apoptosis. Nat Cell Biol.
6:366–372. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Wang M, Chen DQ, Chen L, Liu D, Zhao H,
Zhang ZH, Vaziri ND, Guo Y, Zhao YY and Cao G: Novel RAS inhibitors
poricoic acid ZG and poricoic Acid ZH attenuate renal fibrosis via
a Wnt/β-catenin pathway and targeted phosphorylation of smad3
signaling. J Agric Food Chem. 66:1828–1842. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Takekawa M, Tatebayashi K, Itoh F, Adachi
M, Imai K and Saito H: Smad-dependent GADD45beta expression
mediates delayed activation of p38 MAP kinase by TGF-beta. EMBO J.
21:6473–6482. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Yeh YY, Chiao CC, Kuo WY, Hsiao YC, Chen
YJ, Wei YY, Lai TH, Fong YC and Tang CH: TGF-beta1 increases
motility and alphavbeta3 integrin up-regulation via PI3K, Akt and
NF-kappaB-dependent pathway in human chondrosarcoma cells. Biochem
Pharmacol. 75:1292–1301. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Ogawa K, Chen F, Kuang C and Chen Y:
Suppression of matrix metalloproteinase-9 transcription by
transforming growth factor-beta is mediated by a nuclear
factor-kappaB site. Biochem J. 381:413–422. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Liu HJ, Miao H, Yang JZ, Liu F, Cao G and
Zhao YY: Deciphering the role of lipoproteins and lipid metabolic
alterations in ageing and ageing-associated renal fibrosis. Ageing
Res Rev. 85:1018612023. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Liu Y: kidney fibrosis: Fundamental
questions, challenges, and perspectives. Integr Med Nephrol Androl.
11:e24–00027. 2024. View Article : Google Scholar
|
|
76
|
Wang Y, Guo J, Shao B, Chen H and Lan H:
The Role of TGF-β1/SMAD in diabetic nephropathy: Mechanisms and
research development. Sichuan Da Xue Xue Bao Yi Xue Ban.
54:1065–1073. 2023.In Chinese.
|
|
77
|
Zhang J, Cao L, Wang X, Li Q, Zhang M,
Cheng C, Yu L, Xue F, Sui W, Sun S, et al: The E3 ubiquitin ligase
TRIM31 plays a critical role in hypertensive nephropathy by
promoting proteasomal degradation of MAP3K7 in the TGF-β1 signaling
pathway. Cell Death Differ. 29:556–567. 2022. View Article : Google Scholar
|
|
78
|
Dan Hu Q, Wang HL, Liu J, He T, Tan RZ,
Zhang Q, Su HW, Kantawong F, Lan HY and Wang L: Btg2 promotes focal
segmental glomerulosclerosis via smad3-dependent
podocyte-mesenchymal transition. Adv Sci (Weinh). 10:e23043602023.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Chalkia A, Gakiopoulou H, Theohari I,
Foukas PG, Vassilopoulos D and Petras D: Transforming growth
factor-β1/Smad signaling in glomerulonephritis and its association
with progression to chronic kidney disease. Am J Nephrol.
52:653–665. 2021. View Article : Google Scholar
|
|
80
|
Chen L, Yang T, Lu DW, Zhao H, Feng YL,
Chen H, Chen DQ, Vaziri ND and Zhao YY: Central role of
dysregulation of TGF-β/Smad in CKD progression and potential
targets of its treatment. Biomed Pharmacother. 101:670–681. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Zhang W, Li X, Tang Y, Chen C, Jing R and
Liu T: miR-155-5p implicates in the pathogenesis of renal fibrosis
via targeting SOCS1 and SOCS6. Oxid Med Cell Longev.
2020:62639212020.PubMed/NCBI
|
|
82
|
Wang R, Wu G, Dai T, Lang Y, Chi Z, Yang S
and Dong D: Naringin attenuates renal interstitial fibrosis by
regulating the TGF-β/Smad signaling pathway and inflammation. Exp
Ther Med. 21:662021. View Article : Google Scholar
|
|
83
|
Mai X, Shang J, Chen Q, Gu S, Hong Y, Zhou
J and Zhang M: Endophilin A2 protects against renal fibrosis by
targeting TGF-β/Smad signaling. FASEB J. 36:e226032022. View Article : Google Scholar
|
|
84
|
El-Waseif EG, Sharawy MH and Suddek GM:
The modulatory effect of sodium molybdate against cisplatin-induced
CKD: Role of TGF-β/Smad signaling pathway. Life Sci.
306:1208452022. View Article : Google Scholar
|
|
85
|
Zou X, Wu M, Tu M, Tan X, Long Y, Xu Y and
Li M: 4-Octyl itaconate inhibits high glucose induced renal tubular
epithelial cell fibrosis through TGF-β-ROS pathway. J Recept Signal
Transduct Res. 44:27–34. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Wang L, Zha H, Huang J and Shi L: Flavin
containing monooxygenase 2 regulates renal tubular cell fibrosis
and paracrine secretion via SMURF2 in AKI-CKD transformation. Int J
Mol Med. 52:1102023. View Article : Google Scholar :
|
|
87
|
Kurzhagen JT, Dellepiane S, Cantaluppi V
and Rabb H: AKI: An increasingly recognized risk factor for CKD
development and progression. J Nephrol. 33:1171–1187. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Rayego-Mateos S, Marquez-Expósito L,
Rodrigues-Diez R, Sanz AB, Guiteras R, Doladé N, Rubio-Soto I,
Manonelles A, Codina S, Ortiz A, et al: Molecular mechanisms of
kidney injury and repair. Int J Mol Sci. 23:15422022. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Zhao M, Wang Y, Li L, Liu S, Wang C, Yuan
Y, Yang G, Chen Y, Cheng J, Lu Y and Liu J: Mitochondrial ROS
promote mitochondrial dysfunction and inflammation in ischemic
acute kidney injury by disrupting TFAM-mediated mtDNA maintenance.
Theranostics. 11:1845–1863. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Canaud G and Bonventre JV: Cell cycle
arrest and the evolution of chronic kidney disease from acute
kidney injury. Nephrol Dial Transplant. 30:575–583. 2015.
View Article : Google Scholar :
|
|
91
|
Wang Z and Zhang C: From AKI to CKD:
Maladaptive repair and the underlying mechanisms. Int J Mol Sci.
23:108802022. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Wu M, Chen W, Miao M, Jin Q, Zhang S, Bai
M, Fan J, Zhang Y, Zhang A, Jia Z and Huang S: Anti-anemia drug
FG4592 retards the AKI-to-CKD transition by improving vascular
regeneration and antioxidative capability. Clin Sci (Lond).
135:1707–1726. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Huang R, Fu P and Ma L: Kidney fibrosis:
From mechanisms to therapeutic medicines. Signal Transduct Target
Ther. 8:1292023. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Li L, Fu H and Liu Y: The fibrogenic niche
in kidney fibrosis: Components and mechanisms. Nat Rev Nephrol.
18:545–557. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Zheng D, Liu J, Piao H, Zhu Z, Wei R and
Liu K: ROS-triggered endothelial cell death mechanisms: Focus on
pyroptosis, parthanatos, and ferroptosis. Front Immunol.
13:10392412022. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Molema G, Zijlstra JG, van Meurs M and
Kamps JAAM: Renal microvascular endothelial cell responses in
sepsis-induced acute kidney injury. Nat Rev Nephrol. 18:95–112.
2022. View Article : Google Scholar
|
|
97
|
Jourde-Chiche N, Fakhouri F, Dou L,
Bellien J, Burtey S, Frimat M, Jarrot PA, Kaplanski G, Le Quintrec
M, Pernin V, et al: Endothelium structure and function in kidney
health and disease. Nat Rev Nephrol. 15:87–108. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Aranda-Rivera AK, Cruz-Gregorio A,
Aparicio-Trejo OE and Pedraza-Chaverri J: Mitochondrial redox
signaling and oxidative stress in kidney diseases. Biomolecules.
11:11442021. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Kishi S, Nagasu H, Kidokoro K and
Kashihara N: Oxidative stress and the role of redox signalling in
chronic kidney disease. Nat Rev Nephrol. 20:101–119. 2024.
View Article : Google Scholar
|
|
100
|
Fontecha-Barriuso M, Martin-Sanchez D,
Martinez-Moreno JM, Monsalve M, Ramos AM, Sanchez-Niño MD,
Ruiz-Ortega M, Ortiz A and Sanz AB: The role of PGC-1α and
mitochondrial biogenesis in kidney diseases. Biomolecules.
10:3472020. View Article : Google Scholar
|
|
101
|
Zhang X, Agborbesong E and Li X: The role
of mitochondria in acute kidney injury and chronic kidney disease
and its therapeutic potential. Int J Mol Sci. 22:112532021.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Grgic I, Duffield JS and Humphreys BD: The
origin of interstitial myofibroblasts in chronic kidney disease.
Pediatr Nephrol. 27:183–193. 2012. View Article : Google Scholar
|
|
103
|
Yeh TH, Tu KC, Wang HY and Chen JY: From
acute to chronic: Unraveling the pathophysiological mechanisms of
the progression from acute kidney injury to acute kidney disease to
chronic kidney Disease. Int J Mol Sci. 25:17552024. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Liu J, Kumar S, Dolzhenko E, Alvarado GF,
Guo J, Lu C, Chen Y, Li M, Dessing MC, Parvez RK, et al: Molecular
characterization of the transition from acute to chronic kidney
injury following ischemia/reperfusion. JCI Insight. 2:e947162017.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Li H, Hu L, Zheng C, Kong Y, Liang M and
Li Q: Ankrd1 as a potential biomarker for the transition from acute
kidney injury to chronic kidney disease. Sci Rep. 15:46592025.
View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Wen Y, Xu L, Melchinger I,
Thiessen-Philbrook H, Moledina DG, Coca SG, Hsu CY, Go AS, Liu KD,
Siew ED, et al: Longitudinal biomarkers and kidney disease
progression after acute kidney injury. JCI Insight. 8:e1677312023.
View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Muto Y, Dixon EE, Yoshimura Y, Wu H,
Omachi K, Ledru N, Wilson PC, King AJ, Eric Olson N, Gunawan MG, et
al: Defining cellular complexity in human autosomal dominant
polycystic kidney disease by multimodal single cell analysis. Nat
Commun. 13:64972022. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Kirita Y, Wu H, Uchimura K, Wilson PC and
Humphreys BD: Cell profiling of mouse acute kidney injury reveals
conserved cellular responses to injury. Proc Natl Acad Sci USA.
117:15874–15883. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Ma T, Li H, Liu H, Peng Y, Lin T, Deng Z,
Jia N, Chen Z and Wang P: Neat1 promotes acute kidney injury to
chronic kidney disease by facilitating tubular epithelial cells
apoptosis via sequestering miR-129-5p. Mol Ther. 30:3313–3332.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Zheng Z, Xu K, Li C, Qi C, Fang Y, Zhu N,
Bao J, Zhao Z, Yu Q, Wu H and Liu J: NLRP3 associated with chronic
kidney disease progression after ischemia/reperfusion-induced acute
kidney injury. Cell Death Discov. 7:3242021. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Fu Y, Xiang Y, Wang Y, Liu Z, Yang D, Zha
J, Tang C, Cai J, Chen G and Dong Z: The STAT1/HMGB1/NF-κB pathway
in chronic inflammation and kidney injury after cisplatin exposure.
Theranostics. 13:2757–2773. 2023. View Article : Google Scholar :
|
|
112
|
Cui N, Liu C, Tang X, Song L, Xiao Z, Wang
C, Wu Y, Zhou Y, Peng C, Liu Y, et al: ISG15 accelerates acute
kidney injury and the subsequent AKI-to-CKD transition by promoting
TGFβR1 ISGylation. Theranostics. 14:4536–4553. 2024. View Article : Google Scholar :
|
|
113
|
Doke T, Mukherjee S, Mukhi D, Dhillon P,
Abedini A, Davis JG, Chellappa K, Chen B, Baur JA and Susztak K:
NAD+ precursor supplementation prevents
mtRNA/RIG-I-dependent inflammation during kidney injury. Nat Metab.
5:414–430. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Cai Y, Chen J, Liu J, Zhu K, Xu Z, Shen J,
Wang D and Chu L: Identification of six hub genes and two key
pathways in two rat renal fibrosis models based on bioinformatics
and RNA-seq transcriptome analyses. Front Mol Biosci.
9:10357722022. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Berezin AE, Berezina TA, Hoppe UC,
Lichtenauer M and Berezin AA: An overview of circulating and
urinary biomarkers capable of predicting the transition of acute
kidney injury to chronic kidney disease. Expert Rev Mol Diagn.
24:627–647. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Puri B, Majumder S and Gaikwad AB: Novel
dysregulated long non-coding RNAs in the acute kidney
injury-to-chronic kidney diseases transition unraveled by
transcriptomic analysis. Pharmacol Res Perspect. 12:e700362024.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Badurdeen Z, Alli-Shaik A, Ratnatunga NVI,
Abeysekera TDJ, Wijetunge S, Hemage RKD, Fernando BNTW,
Hettiarachchi TW, Gunaratne J and Nanayakkara N: Serum transforming
growth factor-beta 1 and creatinine for early diagnosis of CKD of
unknown or uncertain etiology phenotypes. Kidney Int Rep.
8:368–372. 2022. View Article : Google Scholar
|
|
118
|
Wu W, Wang X, Yu X and Lan HY: Smad3
signatures in renal inflammation and fibrosis. Int J Biol Sci.
18:2795–2806. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Kuang Q, Wu S, Xue N, Wang X, Ding X and
Fang Y: Selective Wnt/β-Catenin pathway activation concomitant with
sustained overexpression of miR-21 is responsible for aristolochic
acid-induced AKI-to-CKD transition. Front Pharmacol. 12:6672822021.
View Article : Google Scholar
|
|
120
|
Nath KA, Croatt AJ, Warner GM and Grande
JP: Genetic deficiency of Smad3 protects against murine ischemic
acute kidney injury. Am J Physiol Renal Physiol. 301:F436–F442.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Yan Z, Wang G and Shi X: Advances in the
progression and prognosis biomarkers of chronic kidney disease.
Front Pharmacol. 12:7853752021. View Article : Google Scholar
|
|
122
|
González-Nicolás MÁ, González-Guerrero C,
Goicoechea M, Boscá L, Valiño-Rivas L and Lázaro A: Biomarkers in
contrast-induced acute kidney injury: Towards A new perspective.
Int J Mol Sci. 25:34382024. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Wang JY, Gao YB, Zhang N, Zou DW, Wang P,
Zhu ZY, Li JY, Zhou SN, Wang SC, Wang YY and Yang JK: miR-21
overexpression enhances TGF-β1-induced epithelial-to-mesenchymal
transition by target smad7 and aggravates renal damage in diabetic
nephropathy. Mol Cell Endocrinol. 392:163–172. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Tsuji K, Nakanoh H, Fukushima K, Kitamura
S and Wada J: MicroRNAs as biomarkers and therapeutic targets for
acute kidney injury. Diagnostics (Basel). 13:28932023. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Chen C, Lu C, Qian Y, Li H, Tan Y, Cai L
and Weng H: Urinary miR-21 as a potential biomarker of hypertensive
kidney injury and fibrosis. Sci Rep. 7:177372017. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Lv LL, Cao YH, Ni HF, Xu M, Liu D, Liu H,
Chen PS and Liu BC: MicroRNA-29c in urinary exosome/microvesicle as
a biomarker of renal fibrosis. Am J Physiol Renal Physiol.
305:F1220–F1227. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
He L, Wei Q, Liu J, Yi M, Liu Y, Liu H,
Sun L, Peng Y, Liu F, Venkatachalam MA and Dong Z: AKI on CKD:
Heightened injury, suppressed repair, and the underlying
mechanisms. Kidney Int. 92:1071–1083. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Lu Y, Xu S, Tang R, Han C and Zheng C: A
potential link between fibroblast growth factor-23 and the
progression of AKI to CKD. BMC Nephrol. 24:872023. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Gifford CC, Lian F, Tang J, Costello A,
Goldschmeding R, Samarakoon R and Higgins PJ: PAI-1 induction
during kidney injury promotes fibrotic epithelial dysfunction via
deregulation of klotho, p53, and TGF-β1-receptor signaling. FASEB
J. 35:e217252021. View Article : Google Scholar
|
|
130
|
Paniagua-Sancho M, Quiros Y, Casanova AG,
Blanco-Gozalo V, Agüeros-Blanco C, Benito-Hernández A, Ramos-Barron
MA, Gómez-Alamillo C, Arias M, Sancho-Martínez SM and
López-Hernández FJ: Urinary plasminogen activator inhibitor-1: A
biomarker of acute tubular injury. Am J Nephrol. 52:714–724. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Yang L, Si P, Kuerban T, Guo L, Zhan S,
Zuhaer Y, Zuo Y, Lu P, Bai X and Liu T: UHRF1 promotes
epithelial-mesenchymal transition mediating renal fibrosis by
activating the TGF-β/SMAD signaling pathway. Sci Rep. 15:33462025.
View Article : Google Scholar
|
|
132
|
Livingston MJ, Shu S, Fan Y, Li Z, Jiao Q,
Yin XM, Venkatachalam MA and Dong Z: Tubular cells produce FGF2 via
autophagy after acute kidney injury leading to fibroblast
activation and renal fibrosis. Autophagy. 19:256–277. 2023.
View Article : Google Scholar :
|
|
133
|
Ren LL, Miao H, Wang YN, Liu F, Li P and
Zhao YY: TGF-β as A master regulator of aging-associated tissue
fibrosis. Aging Dis. 14:1633–1650. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Fei S, Ma Y, Zhou B, Chen X, Zhang Y, Yue
K, Li Q, Gui Y, Xiang T, Liu J, et al: Platelet membrane biomimetic
nanoparticle-targeted delivery of TGF-β1 siRNA attenuates renal
inflammation and fibrosis. Int J Pharm. 659:1242612024. View Article : Google Scholar
|
|
135
|
Wang B, Ding X, Ding C, Tesch G, Zheng J,
Tian P, Ricardo S, Shen HH and Xue W: WNT1-inducible-signaling
pathway protein 1 regulates the development of kidney fibrosis
through the TGF-β1 pathway. FASEB J. 34:14507–14520. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Wang H, Wang B, Zhang A, Hassounah F, Seow
Y, Wood M, Ma F, Klein JD, Price SR and Wang XH: Exosome-mediated
miR-29 transfer reduces muscle atrophy and kidney fibrosis in mice.
Mol Ther. 27:571–583. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Wang B, Jha JC, Hagiwara S, McClelland AD,
Jandeleit-Dahm K, Thomas MC, Cooper ME and Kantharidis P:
Transforming growth factor-β1-mediated renal fibrosis is dependent
on the regulation of transforming growth factor receptor 1
expression by let-7b. Kidney Int. 85:352–361. 2014. View Article : Google Scholar
|
|
138
|
Qin W, Chung AC, Huang XR, Meng XM, Hui
DS, Yu CM, Sung JJ and Lan HY: TGF-β/Smad3 signaling promotes renal
fibrosis by inhibiting miR-29. J Am Soc Nephrol. 22:1462–1474.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Kato M, Arce L, Wang M, Putta S, Lanting L
and Natarajan R: A microRNA circuit mediates transforming growth
factor-β1 autoregulation in renal glomerular mesangial cells.
Kidney Int. 80:358–368. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Singh SP, Tao S, Fields TA, Webb S, Harris
RC and Rao R: Glycogen synthase kinase-3 inhibition attenuates
fibroblast activation and development of fibrosis following renal
ischemia-reperfusion in mice. Dis Model Mech. 8:931–940.
2015.PubMed/NCBI
|
|
141
|
Wang X, Feng S, Fan J, Li X, Wen Q and Luo
N: New strategy for renal fibrosis: Targeting Smad3 proteins for
ubiquitination and degradation. Biochem Pharmacol. 116:200–209.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Jinnin M, Ihn H and Tamaki K:
Characterization of SIS3, a novel specific inhibitor of Smad3, and
its effect on transforming growth factor-beta1-induced
extracellular matrix expression. Mol Pharmacol. 69:597–607. 2006.
View Article : Google Scholar
|
|
143
|
Lan HY: Smad7 as a therapeutic agent for
chronic kidney diseases. Front Biosci. 13:4984–4992. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Meng XM, Chung AC and Lan HY: Role of the
TGF-β/BMP-7/Smad pathways in renal diseases. Clin Sci (Lond).
124:243–254. 2013. View Article : Google Scholar
|
|
145
|
Kim S, Jeong CH, Song SH, Um JE, Kim HS,
Yun JS, Han D, Cho ES, Nam BY, Yook JI, et al: Micellized protein
transduction domain-bone morphogenetic protein-7 efficiently blocks
renal fibrosis via inhibition of transforming growth
factor-beta-mediated epithelial-mesenchymal transition. Front
Pharmacol. 11:5912752020. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Liu R, Das B, Xiao W, Li Z, Li H, Lee K
and He JC: A novel inhibitor of homeodomain interacting protein
kinase 2 mitigates kidney fibrosis through inhibition of the
TGF-β1/Smad3 pathway. J Am Soc Nephrol. 28:2133–2143. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Chang X, Zhen X, Liu J, Ren X, Hu Z, Zhou
Z, Zhu F, Ding K and Nie J: The antihelmenthic phosphate
niclosamide impedes renal fibrosis by inhibiting
homeodomain-interacting protein kinase 2 expression. Kidney Int.
92:612–624. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Zhang Z, Li Z, Cao K, Fang D, Wang F, Bi
G, Yang J, He Y, Wu J, Wei Y and Song X: Adjunctive therapy with
statins reduces residual albuminuria/proteinuria and provides
further renoprotection by downregulating the angiotensin II-AT1
pathway in hypertensive nephropathy. J Hypertens. 35:1442–1456.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Tian T, Zhang J, Zhu X, Wen S, Shi D and
Zhou H: FTY720 ameliorates renal fibrosis by simultaneously
affecting leucocyte recruitment and TGF-β signalling in
fibroblasts. Clin Exp Immunol. 190:68–78. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Zhou X, Zhang J, Xu C and Wang W: Curcumin
ameliorates renal fibrosis by inhibiting local fibroblast
proliferation and extracellular matrix deposition. J Pharmacol Sci.
126:344–350. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Qin T, Yin S, Yang J, Zhang Q, Liu Y,
Huang F and Cao W: Sinomenine attenuates renal fibrosis through
Nrf2-mediated inhibition of oxidative stress and TGFβ signaling.
Toxicol Appl Pharmacol. 304:1–8. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Wang HW, Shi L, Xu YP, Qin XY and Wang QZ:
Oxymatrine inhibits renal fibrosis of obstructive nephropathy by
downregulating the TGF-β1-Smad3 pathway. Ren Fail. 38:945–951.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Liu L, Wang Y, Yan R, Li S, Shi M, Xiao Y
and Guo B: Oxymatrine inhibits renal tubular EMT induced by high
glucose via upregulation of SnoN and inhibition of TGF-β1/Smad
signaling pathway. PLoS One. 11:e01519862016. View Article : Google Scholar
|
|
154
|
Wang DT, Huang RH, Cheng X, Zhang ZH, Yang
YJ and Lin X: Tanshinone IIA attenuates renal fibrosis and
inflammation via altering expression of TGF-β/Smad and NF-κB
signaling pathway in 5/6 nephrectomized rats. Int Immunopharmacol.
26:4–12. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Cheng H, Bo Y, Shen W, Tan J, Jia Z, Xu C
and Li F: Leonurine ameliorates kidney fibrosis via suppressing
TGF-β and NF-κB signaling pathway in UUO mice. Int Immunopharmacol.
25:406–415. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Luo Q, Tian L, Di L, Yan YM, Wei XY, Wang
XF and Cheng YX: (±)-Sinensilactam A, a pair of rare hybrid
metabolites with Smad3 phosphorylation inhibition from Ganoderma
sinensis. Org Lett. 17:1565–1568. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Wang Y, Liu N, Su X, Zhou G, Sun G, Du F,
Bian X and Wang B: Epigallocatechin-3-gallate attenuates
transforming growth factor-β1 induced epithelial-mesenchymal
transition via Nrf2 regulation in renal tubular epithelial cells.
Biomed Pharmacother. 70:260–267. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Zhang L, Li Z, He W, Xu L, Wang J, Shi J
and Sheng M: Effects of astragaloside IV against the TGF-β1-induced
epithelial-to-mesenchymal transition in peritoneal mesothelial
cells by promoting smad 7 expression. Cell Physiol Biochem.
37:43–54. 2015. View Article : Google Scholar
|
|
159
|
Wang L, Chi YF, Yuan ZT, Zhou WC, Yin PH,
Zhang XM, Peng W and Cai H: Astragaloside IV inhibits renal
tubulointerstitial fibrosis by blocking TGF-β/Smad signaling
pathway in vivo and in vitro. Exp Biol Med (Maywood).
239:1310–1324. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Dou F, Ding Y, Wang C, Duan J, Wang W, Xu
H, Zhao X, Wang J and Wen A: Chrysophanol ameliorates renal
interstitial fibrosis by inhibiting the TGF-β/Smad signaling
pathway. Biochem Pharmacol. 180:1140792020. View Article : Google Scholar
|
|
161
|
Chen SJ, Wu P, Sun LJ, Zhou B, Niu W, Liu
S, Lin FJ and Jiang GR: miR-204 regulates epithelial-mesenchymal
transition by targeting SP1 in the tubular epithelial cells after
acute kidney injury induced by ischemia-reperfusion. Oncol Rep.
37:1148–1158. 2017. View Article : Google Scholar
|
|
162
|
Song J, Yu W, Chen S, Huang J, Zhou C and
Liang H: Remimazolam attenuates inflammation and kidney fibrosis
following folic acid injury. Eur J Pharmacol. 966:1763422024.
View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Douvris A, Viñas JL, Gutsol A, Zimpelmann
J, Burger D and Burns KD: miR-486-5p protects against rat ischemic
kidney injury and prevents the transition to chronic kidney disease
and vascular dysfunction. Clin Sci (Lond). 138:599–614. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Játiva S, Torrico S, Calle P, Muñoz Á,
García M, Larque AB, Poch E and Hotter G: NGAL release from
peripheral blood mononuclear cells protects against acute kidney
injury and prevents AKI induced fibrosis. Biomed Pharmacother.
153:1134152022. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Torrico S, Hotter G, Muñoz Á, Calle P,
García M, Poch E and Játiva S: PBMC therapy reduces cell death and
tissue fibrosis after acute kidney injury by modulating the pattern
of monocyte/macrophage survival in tissue. Biomed Pharmacother.
178:1171862024. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Chiang CH, Lan TY, Hsieh JH, Lin SC, Chen
JW and Chang TT: Diosgenin reduces acute kidney injury and
ameliorates the progression to chronic kidney disease by modifying
the NOX4/p65 signaling pathways. J Agric Food Chem. 72:17444–17454.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Xin W, Gong S, Chen Y, Yao M, Qin S, Chen
J, Zhang A, Yu W, Zhou S, Zhang B, et al: Self-assembling P38
peptide inhibitor nanoparticles ameliorate the transition from
acute to chronic kidney disease by suppressing ferroptosis. Adv
Healthc Mater. 13:e24004412024. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Perez-Moreno E, Toledo T, Campusano P,
Zuñiga S, Azócar L, Feuerhake T, Méndez GP, Labarca M, Pérez-Molina
F, de la Peña A, et al: Galectin-8 counteracts folic acid-induced
acute kidney injury and prevents its transition to fibrosis. Biomed
Pharmacother. 177:1169232024. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Barrera-Chimal J, Rocha L, Amador-Martínez
I, Pérez-Villalva R, González R, Cortés-González C, Uribe N,
Ramírez V, Berman N, Gamba G and Bobadilla NA: Delayed
spironolactone administration prevents the transition from acute
kidney injury to chronic kidney disease through improving renal
inflammation. Nephrol Dial Transplant. 34:794–801. 2019. View Article : Google Scholar
|
|
170
|
Li ZL, Wang B, Lv LL, Tang TT, Wen Y, Cao
JY, Zhu XX, Feng ST, Crowley SD and Liu BC: FIH-1-modulated HIF-1α
C-TAD promotes acute kidney injury to chronic kidney disease
progression via regulating KLF5 signaling. Acta Pharmacol Sin.
42:2106–2119. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Guo X, Xu L, Velazquez H, Chen TM,
Williams RM, Heller DA, Burtness B, Safirstein R and Desir GV:
Kidney-targeted renalase agonist prevents cisplatin-induced chronic
kidney disease by inhibiting regulated necrosis and inflammation. J
Am Soc Nephrol. 33:342–356. 2022. View Article : Google Scholar :
|
|
172
|
Czopek A, Moorhouse R, Gallacher PJ, Pugh
D, Ivy JR, Farrah TE, Godden E, Hunter RW, Webb DJ, Tharaux PL, et
al: Endothelin blockade prevents the long-term cardiovascular and
renal sequelae of acute kidney injury in mice. Sci Transl Med.
14:eabf50742022. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Chen Y, Bai X, Chen J, Huang M, Hong Q,
Ouyang Q, Sun X, Zhang Y, Liu J, Wang X, et al: Pyruvate kinase M2
regulates kidney fibrosis through pericyte glycolysis during the
progression from acute kidney injury to chronic kidney disease.
Cell Prolif. 57:e135482024. View Article : Google Scholar :
|
|
174
|
Hu Z, Zhan J, Pei G and Zeng R: Depletion
of macrophages with clodronate liposomes partially attenuates renal
fibrosis on AKI-CKD transition. Ren Fail. 45:21494122023.
View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Gu L, Gao Q, Ni L, Wang M and Shen F:
Fasudil inhibits epithelial-myofibroblast transdifferentiation of
human renal tubular epithelial HK-2 cells induced by high glucose.
Chem Pharm Bull (Tokyo). 61:688–694. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Wang Z, Perez M, Lee ES, Kojima S and
Griffin M: The functional relationship between transglutaminase 2
and transforming growth factor β1 in the regulation of angiogenesis
and endothelial-mesenchymal transition. Cell Death Dis.
8:e30322017. View Article : Google Scholar
|
|
177
|
Cao Y, Su H, Zeng J, Xie Y, Liu Z, Liu F,
Qiu Y, Yi F, Lin J, Hammes HP and Zhang C: Integrin β8 prevents
pericyte-myofibroblast transition and renal fibrosis through
inhibiting the TGF-β1/TGFBR1/Smad3 pathway in diabetic kidney
disease. Transl Res. 265:36–50. 2024. View Article : Google Scholar
|
|
178
|
Li J, Qu X, Yao J, Caruana G, Ricardo SD,
Yamamoto Y, Yamamoto H and Bertram JF: Blockade of
endothelial-mesenchymal transition by a Smad3 inhibitor delays the
early development of streptozotocin-induced diabetic nephropathy.
Diabetes. 59:2612–2624. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Akhurst RJ and Hata A: Targeting the TGFβ
signalling pathway in disease. Nat Rev Drug Discov. 11:790–811.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Peñalva MA, Zhang J, Xiang X and
Pantazopoulou A: Transport of fungal RAB11 secretory vesicles
involves myosin-5, dynein/dynactin/p25, and kinesin-1 and is
independent of kinesin-3. Mol Biol Cell. 28:947–961. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Tzavlaki K and Moustakas A: TGF-β
signaling. Biomolecules. 10:4872020. View Article : Google Scholar
|
|
182
|
Deng Z, Fan T, Xiao C, Tian H, Zheng Y, Li
C and He J: TGF-β signaling in health, disease, and therapeutics.
Signal Transduct Target Ther. 9:612024. View Article : Google Scholar
|
|
183
|
Rodón J, Carducci M, Sepulveda-Sánchez JM,
Azaro A, Calvo E, Seoane J, Braña I, Sicart E, Gueorguieva I,
Cleverly A, et al: Pharmacokinetic, pharmacodynamic and biomarker
evaluation of transforming growth factor-β receptor I kinase
inhibitor, galunisertib, in phase 1 study in patients with advanced
cancer. Invest New Drugs. 33:357–370. 2015. View Article : Google Scholar
|
|
184
|
Kawamura M, Sato S, Matsumoto G, Fukuda T,
Shiba-Fukushima K, Noda S, Takanashi M, Mori N and Hattori N: Loss
of nuclear REST/NRSF in aged-dopaminergic neurons in Parkinson's
disease patients. Neurosci Lett. 699:59–63. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Levey AS, Inker LA, Matsushita K, Greene
T, Willis K, Lewis E, de Zeeuw D, Cheung AK and Coresh J: GFR
decline as an end point for clinical trials in CKD: A scientific
workshop sponsored by the National Kidney Foundation and the US
food and drug administration. Am J Kidney Dis. 64:821–835. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Levey AS, Gansevoort RT, Coresh J, Inker
LA, Heerspink HL, Grams ME, Greene T, Tighiouart H, Matsushita K,
Ballew SH, et al: Change in albuminuria and GFR as end points for
clinical trials in early stages of CKD: A scientific workshop
sponsored by the national kidney foundation in collaboration with
the US food and drug administration and european medicines agency.
Am J Kidney Dis. 75:84–104. 2020. View Article : Google Scholar
|
